WO1992009630A1 - Compositions d'hemoglobine reticulees par un imidoester - Google Patents

Compositions d'hemoglobine reticulees par un imidoester Download PDF

Info

Publication number
WO1992009630A1
WO1992009630A1 PCT/US1991/007155 US9107155W WO9209630A1 WO 1992009630 A1 WO1992009630 A1 WO 1992009630A1 US 9107155 W US9107155 W US 9107155W WO 9209630 A1 WO9209630 A1 WO 9209630A1
Authority
WO
WIPO (PCT)
Prior art keywords
hemoglobin
cross
linked
die
molecular weight
Prior art date
Application number
PCT/US1991/007155
Other languages
English (en)
Inventor
Robert Lee Garlick
Joseph Patrick Martin, Jr.
Stephen Baker Lyle
Original Assignee
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company filed Critical The Upjohn Company
Priority to EP91917174A priority Critical patent/EP0559655B1/fr
Priority to PL91299380A priority patent/PL167340B1/pl
Priority to SK54993A priority patent/SK54993A3/sk
Priority to JP3516187A priority patent/JPH06502848A/ja
Priority to AU85466/91A priority patent/AU650287B2/en
Priority to CZ93854A priority patent/CZ281912B6/cs
Priority to DE69108258T priority patent/DE69108258T2/de
Publication of WO1992009630A1 publication Critical patent/WO1992009630A1/fr
Priority to US08/065,170 priority patent/US5362855A/en
Priority to NO93931956A priority patent/NO931956L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention is directed toward a novel process for producing a purified cross- linked hemoglobin product suitable as a blood replacement for transfusion in human beings and in animals or as an oxygen transport fluid.
  • the subject cross-linked hemoglobin product is essentially free of contaminants in that it contains very low levels of bacterial endotoxin and phospholipid.
  • the structure and function of hemoglobin have been reviewed (Bu ⁇ n, H.F., and B.G. Forget, Hemoglobin: Molecular. Genetic and Clinical Aspects. W.B. Saunders Company, Philadelphia, 690 pp., (1986).
  • Mammalian hemoglobin is a tetramer containing two each of two different types of subunits, alpha and beta.
  • Each subunit is of approximate molecular weight 16,000 and contains a heme group with a central iron atom.
  • the protein portion, or globin functions to keep the heme iron in the reduced or ferrous state, thus to allow the hemoglobin molecule to reversibly bind oxygen.
  • Mammalian hemoglobin should not be thought of as a static tetramer, that is a single protein species with a molecular weight of 64-68,000. It is instead composed of sub-units connected by noncovalent bonds, and existing in dynamic equilibria involving monomer-dimef and dimer-tetramer interactions. At any moment, the hemoglobin would consist of a certain proportion of monomers with a molecular weight of approximately 16,000, dimers of molecular weight 32,000, and tetramers. The distribution of monomer, dimer, and tetramer species in solution are dependent upon hemoglobin concentration, the ligand state of the hemoglobin, as well as pH and salt composition of the solution in which it is contained.
  • Mammalian hemoglobin is contained within red blood cells or erythrocytes. In the mammals these specialized cells have lost their nuclei during maturation, and are simply sacs of hemoglobin containing very low concentrations of other proteins.
  • the hemoglobin is contained with circulating erythrocytes for several reasons. First of all, if the hemoglobin were not in cells but instead circulated free in solution, it would readily be cleared from circulation by passage through the capillary walls, the kidney and other sites. Certain invertebrate organisms have solved this problem by evolving polymeric hemoglobins with molecular weights in the millions which are too large to pass through capillaries and the nephron of the kidney.
  • red cell Other functions served by the red cell are to provide a sheltered environment to protect the hemoglobin molecule from proteolytic serum proteins, maintain a balance of ions proper for hemoglobin function, provide an enzyme system which maintains the heme iron in the reduced (functional) state, and control the presence of aliosteric effector molecules.
  • the subject invention is a stable, cross-linked hemoglobin composition capabl of transporting and releasing oxygen in living cells.
  • the hemoglobin is essentially free o impurities and is cross-linked with an imidoester whereby the hemoglobin is present i predominantly tetramer and larger forms.
  • the preferred imidoesters for cross-linking th hemoglobin are dimethyl adipimidate or dimethyl suberimidate.
  • Hemoglobin predominantly in tetramer or larger form can be interpreted as where at least 80% of the cross-linked hemoglobi has a molecular weight of at least 64,000 Daltons, more preferably where at least 90 to 95% o the cross-linked hemoglobin has a molecular weight of at least 64,000 Daltons.
  • die imidoester cross-linked hemoglobin is very stable to methemoglobin as compared to conventional means of cross-linking and has an oxygen affinity, p50, of at least 13mm Hg.
  • the cross-linked hemoglobin composition can also include a pharmaceutically acceptable carrier medium for facilitating transfusion or injection into a mammal being treated or for use as an oxygen carrying fluid for analytic, transplant or laboratory usage.
  • Typical pharmaceutically acceptable carrier medium can include purified water or saline solution.
  • the subject invention is a method for preparing a cross-linked hemoglobin composition
  • a method for preparing a cross-linked hemoglobin composition comprising a) collecting mammalian blood, b). separating red blood cells from the collected blood and washing die red blood cells, c) lysing die washed red blood cells, d) centrifuging the lysed blood cells to obtain a lysate of hemoglobin, e) purifying the lysate by anion or cation exchange chromatography, f) performing an ultrafiltration or microfiltration of eluted lysate obtained from the chromatography whereby purified hemoglobin is obtained, and g) cross- linking the purified hemoglobin with an imidoester to obtain a hemoglobin present in predominantly tetramer form.
  • the lysing of the red blood cells can be conducted by hypo-osmotic shock.
  • the ultrafiltration is typically conducted with a 300,000 molecular weight membrane and the microf-ltration is typically conducted with from about a 0.025 to about a 0.040 micron filter.
  • cross-linking with imidoester step (g) can be performed after the lysate of hemoglobinis obtained in step (d) whereby step (e) begins with the purification of cross-linked hemoglobin.
  • the method can additional include a step (h) where the purified, cross-linked hemoglobin is size excluded to remove low molecular weight hemoglobin (Jess than 64,000 Daltons).
  • the size exclusion is by low pressure size exclusion chromatography.
  • the present invention therefore describes an imidoester, cross-linked hemoglobin composition essentially free of any impurities and being present in predominantly a tetramer or larger form which has improved stability to oxidation of the hemoglobin over more traditional forms of cross-linking hemoglobin such as with glutaraldehyde.
  • the hemoglobin composition has a predominant molecular weight of at least 64,000 Daltons and has improved cross-link stability.
  • the hemoglobin is suitable for use as a blood oxygen transport substitute for mammals or generally as an oxygen transport fluid.
  • the present invention describes a method for purifying and cross-linking hemoglobin with certain imidoesters which have not been used to cross-link hemoglobin for use as a transfusion therapeutic.
  • These bifunctio ⁇ al imidoester cross-linkers include dimethyl adipimidate and dimethyl suberimidate, among others.
  • Imidoesters such as dimethyl adipimidate and dimethyl suberimidate are bifunctio ⁇ al cross- linking reagents that react specifically and quickly with proteins under mild conditions.
  • Stable, amidine adducts are formed with epsilon-amino groups of lysine residues and the amino terminal amine of polypeptide chains (Wold, F. (1972) Bifunctional reagents. Methods in Enz. 25: 623-651 ;
  • cross-linking reagents and problems in studies of membrane structure. Ann. Rev. Biochem. 4£: 523-551.
  • the cross-linking reagent typically reacts with one-to-two amino groups per hemoglobin subunit. Some cross-linking occurs between the two beta chain lysine residues (beta-82) that stabilize the tetrameric form of human hemoglobin.
  • Dimethyl adipimidate has been studied as an antisickling agent for hemoglobin S (Lubin, B.H.,
  • the present invention uses the dimethyl adipimidate to bovine hemoglobin with th intent of forming both stabilized tetramers, caused by introducing intersubunit cross-links betwee the beta-82 lysines, and high molecular weight aggregates of stabilized tetramers, caused b introducing intermolecular cross-links between epsilon-amino groups of separate, stabilized, hemoglobin tetramers.
  • cross-linking hemoglobin with imidoesters, and specifically dimethyl adipimidate is twofold: first, cross-linking will retard d e dissociation of tetrameric hemoglobin o molecular weight 64,000, into 32,000 molecular weight dimers. In unmodified hemoglobin tetrameric and dimeric species are in a dynamic equilibrium. Stabilization of the tetrameric hemoglobin by cross-linking with imidoesters will substantially reduce d e passage of hemoglobin into d e renal tubules by preventing filtration across the membrane of the glomerular capsule.
  • cross-linking will result in the formation of high molecular weight oligomers of the hemoglobin tetramer which would be extremely resistant to renal filtration and more stable to oxidation at physiological temperature than either unmodified hemoglobin or hemoglobin modified with d e cross-linking agent glutaraldehyde.
  • Dimethyl adipimidate is a relatively inexpensive reagent and is available in bulk quantities.
  • the cross-linking process utilizing dimed yl adipimidate lends itself well to scale up.
  • the oxygen binding properties of the various forms of bovine hemoglobin were measured and appear in Table I.
  • the P50 is the partial pressure of oxygen at which 50% of the available sites have bound oxygen.
  • the Hill coefficient or n value is an expression of the cooperativity among the oxygen binding sites with high n values denoting high cooperativity. The P50 values were measured during both the oxygenation and deoxygenation of the hemoglobin solution.
  • the mean P50 values were: 13.5 mM Hg for dimediyladipimidate cross-linked hemoglobin, 14.25 mM Hg for the glutaraldehyde cross-linked hemoglobin and 23.75 mM Hg for unmodified bovine hemoglobin. If extreme cross-linking was carried out with imidoesters or glutaraldehyde, the p50 values for these hemoglobins was greatiy decreased. Also, wid both the imidoesters and glutaraldehyde, cross-linking ofthe hemoglobin reduced its cooperativity with the greater reduction being seen in the glutaraldehyde treated sample.
  • the stability of the various cross-linked hemoglobins was compared and showed the imidoester version to have superior stability. Therefore, the imidoester under proper cross-linking procedures, described below, yielded a better oxygen transport hemoglobin when considering stability and oxygen affinity.
  • the dimediyladipimidate cross-linked, glutaraldehyde cross- linked, and unmodified hemoglobin samples contained 2.5%, 8.0% and 3.5% med emoglobin, respectively, at the start of the incubation.
  • the percentages of methemoglobin were 8.9%, 44.4%, and 8% for the dimethyladipimidate cross-linked, glutaraldehyde cross-linked, and unmodified bovine hemoglobin samples, respectively.
  • die methemoglobin concentrations were 24.1, 87.9, and 42% for die dimethyladipimidate cross-linked, glutaraldehyde cross-linked, and unmodified bovine hemoglobin samples, respectively.
  • methemoglobin concentrations in dimediyladipimidate cross-linked and uncross- linked bovine hemoglobin samples were 46.5% and 68%, respectively.
  • the dimediyladipimidate cross-linked hemoglobin was more stable than unmodified hemoglobin toticianmoglobin formation.
  • the literature reports that glutaraldehyde cross-linked human hemoglobin autooxidizes at a rate four times higher than unmodified human hemoglobin. Therefore, it was unexpected that the DMA cross-linked hemoglobin would be more stable than unmodified hemoglobin.
  • the invention relates to the enhancement of stability for mammalia hemoglobins including bovine hemoglobin, after cross-linking with imidoesters including dimethy adipimidate. It is disclosed herein mat the stability of mammalian hemoglobins can be enhance by reaction wid imidoesters, specifically dimediyl adipimidate under specific reaction conditions.
  • a method for producing purified mammalian hemoglobin, specifically bovin hemoglobin is also disclosed.
  • the hemoglobin would be essentially free of impurities which mean that it would not contain any materials in a quantity which would cause any deleterious effects t the mammal treated.
  • the hemoglobin would be sufficiendy free of endotoxin (for example, les than 0.5 EU/ml at least a 40 mg/ml concentration of hemoglobin), phospholipid, viruses, and othe nonhemoglobin proteins prior to cross-linking.
  • endotoxin for example, les than 0.5 EU/ml at least a 40 mg/ml concentration of hemoglobin
  • phospholipid for example, phospholipid, viruses, and othe nonhemoglobin proteins prior to cross-linking.
  • viruses for example, les than 0.5 EU/ml at least a 40 mg/ml concentration of hemoglobin
  • othe nonhemoglobin proteins prior to cross-linking.
  • the purified and cross linked hemoglobin would be suitable as an oxygen transporting blood extender for transfusion into
  • the hemoglobin of die subject invention would be prepared by collecting die mammalian blood under aseptic conditions, washing the red cells, lysing d e red cells, centrifuging die lysate, either ultrafiltrating with at least a 300,000 molecular weight membrane or microfiltrating with a 0.025 to about a 0.040 micron filter, purifying by anion or cation exchange chromatography to obtain a purified hemoglobin, then cross-linking with d e imidoester and optionally performing a size exclusion chromatography or ultrafiltration to remove any low molecular weight hemoglobin.
  • the hemoglobin may have been cross-linked after centrifuging and collecting the lysate.
  • the purification steps could then be carried out including die optional size exclusion step.
  • the hemoglobin thus prepared would be essentially free of impurities and consist predominandy of a stabilized tetramer.
  • Another way to characterize the cross-linked hemoglobin would be to state that it has a molecular weight distribution of predominantly at least 64,000.
  • Predominantly or predominant as used herein means at least 80% of die cross-linked hemoglobin, preferably 90 to 95% of the cross-linked hemoglobin.
  • various cross- linking reaction parameters are specified.
  • the concentration of chloride ion, and/or sodium chloride has a profound effect on the extent of cross-linking of (bovine) hemoglobin with DMA over the range of from 1 mM Tris-HCl to 50 mM Tris-HCl plus 2.0 M NaCl.
  • 1 and 10 mM Tris-HCl after 10 additions of DMA, 90.3% and 72.2% (respectively) of the hemoglobin remained unpolymerized.
  • 50 mM Tris-HCl plus 0.5, 0, and 2.0 M NaCl only 25.8, 24.4, and 20.7% remained uncross-Iinked (respectively).
  • buffer type was shown to have a strong influence on cross-linking. For example, the DMA cross-linking reaction proceeded poorly in glycine-HCl, ethanolamine-HCl, and in a solution containing sodium phosphate plus lysine.
  • the next four buffers in terms of DMA cross-linking efficiency were Tris (Tris[hydroxymethyl]aminomethane), sodium carbonate, CHES (2-[N- Cyclohexylaminojedianesulfonic acid), and CAPSO (3-[Cyclohexyl-amino]-2-hydroxy-l- propanesulfonic acid); three of which have primary amino functionalities.
  • CAPS 3- [Cyclohexylamino]-l-propanesulfonic acid
  • Sodium phosphate also was not a good choice for die cross-linking reaction.
  • Typical pharmaceutically acceptable carrier medium can include physiologically acceptable s solutions appropriate for injection or infusion such as saline solutions which are commercial available.
  • a pharmaceutical acceptable carrier would be any of a variety of liquids which wou be relatively inert to the cross-linked hemoglobin and would not have deleterious effect on t mammal being infused or injected.
  • Suitable fluids can also include other blood products eidi natural or synthetic or fluorocarbon fluids.
  • die subject cross-linked hemoglobin wou be admixed in a suitable pharmaceutical carrier whereby die hemoglobin concentration could administered in adequate amount of from about 40 to about 140 mg/ml.
  • Blood was drawn in an aseptic manner from Holstein steers at the farm belonging to T Upjohn Company Agricultural Division. First, die hair was shaved from the neck of each ste with electrical clippers. The shaved area then was wiped with a clotii towel soaked in an iodi solution, followed by washing with 95% ethanol from a squirt botde. The ethanol was allowe to air dry prior to blood drawing.
  • the blood was drawn into 0.5 - 1.0 liter evacuated bloo collection botdes which were sterile and pyrogen ree. An appropriate amount of a sterile sodiu heparin solution was added to each botde prior to blood collection. The botdes were placed on ic immediately after filling, and were transported to the laboratory on ice. For initial studies, 2.5- 5. liters of blood were drawn.
  • the purificatio steps should be conducted in a clean environment with filtered air that has a low particulat content.
  • the first steps in the purification ofthe hemoglobin involve die separation ofthe red bloo cells from the blood plasma, followed by repeated washings of the red cells with a salt solutio and centrifugation to pellet the red cells.
  • the whole blood first was transferred to pyrogen-free 0. liter centrifuge botdes and centrifuged for 30 - 40 minutes at 4000 RPM and 4 ⁇ C The red cell were pelleted during d e centrifugation.
  • the blood plasma in the supernatant was removed b aspiration.
  • the red blood cells or erythrocytes were resuspended in an ice cold solution containin 16 grams of sodium chloride (NaCl) per liter of purified water. This solution is referred to as 1.6% saline.
  • the red cells were resuspended by stirring with a sterile and pyrogen-free glass rod, or by gende repeated inversion of d e centrifuge botde. After d e red cells were resuspended, they were recentrifuged at 10,000 RPM for 30-40 minutes at 4° C.
  • the red cells were resuspended in 1.6% saline and centrifuged again at 10,000 RPM for 30-40 minutes at 4° C. The red cells were washed witii 1.6% saline a total of three times prior to red cell rupture or lysing.
  • die red cells were lysed by hypo-osmotic shock in the following manner. To one volume of washed, pelleted red cells were added four volumes of ice cold 0.0025
  • the red cells were suspended in this dilute phosphate buffer by gende inversion of the centrifuge botdes. After the cells were completely suspended, the red cell suspensions were incubated at 0-4° C for one hour, followed by centrifugation at 10,000 RPM for 30-90 minutes at 4° C After centrifugation, die hemoglobin in d e supernatant was recovered by aspiration.
  • the protocol was modified in die following manner. After d e one hour incubation with 0.0025 M sodium phosphate buffer at 0-4° C, a 2.0 M solution of sodium chloride was added to a final concentration of 0.2 M prior to centrifugation. Addition of die sodium chloride to the red cell lysate provided a clearer supernatant after centrifugation.
  • a polishing step may be included after d e centrifugation to produce die hemolysate.
  • a filter aid which is eidier a cellulosic, diatomaceous earth, polymer, or silica derivative would be added to the centrifuged hemolysate with agitation. The filter aid would then be removed by filtration or centrifugation. Addition of a polishing step with a filter aid would remove additional stroma fragments, thus phospholipid, which would not be entirely removed by centrifugation.
  • hypo-osmotic shock for lysing the red cells is mechanical disruption such as with a French press or a larger scale cell homogenizer.
  • the pyrogen content of the four hemolysates processed varied from 0.05 to 0.2 endotoxin units (EU) per ml by the Limulus Amoebocyte Lysate (LAL) pyrogen test. Downstream processing by anion exchange or cation exchange chromatography would remove die last traces of endotoxin and phospholipid.
  • EU endotoxin units
  • LAL Limulus Amoebocyte Lysate
  • die bovine blood is contaminated with viruses, a certain amount of viral load would be removed during washing of die red cells with low speed centrifugation. Another percentage would be removed with the high speed centrifugation of die hemolysate, and would reside in die pellet. Another aliquot would be removed in a polishing step.
  • Microfiltration with a 0.025-0.040 micron filter will gready reduce die titer of most viruses.
  • An Ultipor N66 nylon 66 microfiltration cartridge from Pall Corporation has a 0.04 micron porosity, and would be used to filter die hemolysate prior to further downstream processing.
  • a 300,000 molecular weight cutoff ultrafiltration membrane from Filtron Corporatio is available which inserts into a Pellicon production scale ultrafiltration unit from Amico Corporation. The hemoglobin would pass freely through all of these ultra- and microfiltratio membranes, whereas a proportion of the viruses would be retained. Therefore, a combination o these two filtration membranes would gready reduce d e viral load.
  • Each of these filter types shows low protein retention.
  • the viral content ofthe hemolysate or filtered hemolysate could b reduced by die addition of appropriate detergents, ethylenedinitrilotetraacetic acid, the FDA- approved reagent trinitrobutyl phosphate, or a combination of these additives.
  • hemoglobin can be applied to an anion exchanger so that it binds to die exchanger. Proteinaceous and non-protei ⁇ aceous impurities would be removed from hemoglobin during development of the column. Conditions also can be selected under wh * ich hemoglobin has little or no affinity for the selected anion exchange resin. Under tiiese conditions, d e impurities would be left behind on die column.
  • the principle contaminants present in freshly prepared hemolysate are phospholipids, potentially residual virus which was not removed by upstream processing steps, low levels of bacterial endotoxin, and proteins other than hemoglobin. Endotoxin, phospholipid, and plasma proteins are more negatively charged than hemoglobin and should exhibit a higher affinity for the anion exchanger under the conditions selected. Under die proper loading and eluting conditions, anion exchange chromatography should be useful for resolving hemoglobin from these contaminants. In addition, anion exchange chromatography should further reduce die viral load.
  • the anion exchanger utilized in these experiments was Q-Sepharose Fast Flow from Pharmacia, but it would be expected mat these procedures would work witii a number of commercially available low to mid-pressure anion exchangers that have been developed for protein purification including those with quaternary amine and diethylaminoethyl functionalities.
  • Cation exchange chromatography also has been utilized extensively for the purification of mammalian hemoglobins (Bucci, E. (1981) Preparation of isolated chains of human hemoglobin, Medi. in Enzvmol. 7fi: 97-106). Under the proper pH and ionic strength conditions, hemoglobin can be applied to a cation exchanger so that it binds to the exchanger.
  • Phospholipid and endotoxin, as well as plasma proteins should have little affinity for the cation exchanger under conditions with which hemoglobin would bind. Under d e proper loading and elution conditions, cation exchange chromatography should be useful for resolving hemoglobin from these contaminants. In addition, cation exchange chromatography would give an additional reduction in viral load.
  • Two cation exchange chromatographic protocols were designed for the purification of hemoglobin.
  • the hemoglobin was loaded wider conditions in which it bound to die cation exchanger and was then eluted with a linear pH gradient.
  • die hemoglobin was loaded under conditions in which it binds to die resin, and then eluted with a step pH gradient.
  • the phospholipid and endotoxin would pass unretarded through the resin, thus resolving these contaminants from the hemoglobin.
  • a number of commercially available cation exchangers would be adequate.
  • a S-Sepharose Fast Flow from Pharmacia was used for its excellent protein binding and flow characteristics.
  • This experiment provided a demonstration of anion exchange chromatography conditions in which bovine hemoglobin was loaded onto the exchanger and then eluted witii a linear pH gradient.
  • a 2.5 X 5.5 cm column of Q-Sepharose Fast Flow was prepared and cleaned by overnight exposure to 0.5 M NaOH. The column was washed with 100 mM Tris, pH 8.5 until die pH of the column effluent was 8.5. The column tiien was equilibrated witii 50 M Tris, pH 8.5.
  • This experiment provided a demonstration of anion exchange chromatography conditions in which bovine hemoglobin was loaded onto the exchanger and then eluted widi a single pH step gradient.
  • a 2.5 X 5.5 cm column of Q-Sepharose Fast Flow was prepared and cleaned as in
  • Example 3A Eight ml of a sample of bovine red cell hemolysate containing approximately 400 mg of hemoglobin were diluted to 16 ml with 50 M Tris, pH 8.5 and loaded onto the column at 2.7 ml per min. Following loading die column was washed widi 50 mM Tris, pH 8.5 until the absorbance of the effluent returned to baseline. The column men was developed widi 50 mM Tris, pH 7.4 and die hemoglobin eluted from the column essentially as a single peak. The amount o hemoglobin present in die Q-Sepharose rich fraction was nearly identical to that loaded onto die column, indicating a nearly quantitative recovery across this step.
  • Example 3C Anion exchange chromatography in which the hemoglobin is not retained
  • This experiment was a demonstration of anion exchange chromatography conditions in which die bovine hemoglobin did not bind to the anion exchanger, but passed dirough the column un-retained.
  • a 2.5 X 5.5 cm column of Q-Sepharose Fast Flow was prepared and cleaned by overnight exposure to 0.5 M NaOH. Die column was washed widi 100 mM Tris, pH 7.4 until die pH of die column effluent measured 7.4.
  • Ten ml of a freshly prepared bovine red cell hemolysate containing 880 mg of hemoglobin were diluted to 40 ml with 50 mM Tris, pH 7.4, and 35 ml were loaded onto die column at 2.5 ml per min.
  • This experiment was a demonstration of cation exchange chromatography conditions in which bovine hemoglobin was loaded onto die exchanger and then eluted widi a linear pH gradient.
  • a 2.5 X 5.5 cm column of S-Sepharose Fast Flow was prepared and cleaned by overnight exposure to 0.5 M NaOH. The column was washed widi 100 mM Bis-Tris, pH 6.0 until d e pH of die column effluent reached 6.0. The column then was equilibrated widi 50 mM Bis-Tris, pH 6.0.
  • the cross-linking reaction was carried out at a hemoglobin tetramer concentration of 1.75 mM. or 112 mg/ml. High tetramer concentrations promote die intermolecular cross-linking of hemoglobin tetramers.
  • the hemoglobin is modified in die presence of 50 mM Tris buffer, pH 8.8 at 4° C.
  • the hemoglobin is modified by die addition of dimediyl adipimidate in equimolar amounts (i.e. 1.75 mM dimediyl adipimidate and 1.75 mM hemoglobin tetramer).
  • the dimediyl adipimidate treatment is repeated eight times at 30 minute intervals at 4°C.
  • a 50 mg/ml solution of dimethyl adipimidate in 0.025 M sodium carbonate, pH 9.25 is added to the hemoglobin solution to a final concentration of 1.75 mM.
  • the hemoglobin solution is vortexed during addition ofthe cross-linker reagent, and tiien incubated on ice for 30 min. After 30 minutes a 0.4 ml sample was withdrawn and added to 4 ml of 0.25 M sodium phosphate, pH 7.0.
  • the phosphate buffer quenches die cross-linker reaction by hydrolysis of die imidoester. Quenching is carried out over two hours at room temperature. The remaining hemoglobin solution is again reacted with a fresh solution of the cross-linking agent.
  • Hemoglobin concentration was determined spectrophotometrically using published extinction coefficients (Benesch, R.E., Benesch R., S. Yung, (1973) Equations for the spectrophotometric analysis of hemoglobin mixtures. Analvt. Biochem. 55: 245-48). Reaction products were monitored after each addition of cross-linker using size exclusion HPLC (SEC- HPLC). Quenched reaction product was diluted to 1 mg hemoglobin tetramer per ml in 0.Z ⁇ M sodium phosphate, pH 7.0. The diluted product was analyzed by SEC-HPLC in two separate modes.
  • the first was a Zorbax GF-250 SEC column (Dupont) equilibrated with 0.2 M sodium phosphate, pH 7.0 and run at 1 ml/min.
  • the second was a Superose 12 FPLC column (Pharmacia) equilibrated in 0.1 M sodium phosphate, pH 7.0. Both columns had been calibrated with proteins of known molecular weight.
  • SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • the P50 values (oxygen partial pressure at half saturation) for the hemoglobin species were: 13.5 mm Hg for the dimethyl adipimidate cross-linked hemoglobin, 14.25 mm Hg for the glutaraldehyde cross-linked hemoglobin, and 23.75 mm Hg for unmodified bovine hemoglobin.
  • Example 8 Stability studies on cross-linked and non-cross-linked bovine hemoglobin
  • Bovine hemoglobin which had been subjected to seven iterations of cross-linking with dimediyl adipimidate, unmodified bovine hemoglobin, and glutaraldehyde cross-linked hemoglobin were subjected to incubation at 36-37° C in 0.125 M sodium phosphate, pH 7.1.
  • the hemoglobin concentrations were 40 mg/ml for dimediyl adipimidate cross-linked bovine hemoglobin and unmodified bovine hemoglobin, and 28 mg/ml for glutaraldehyde cross-linked bovine hemoglobin.
  • Dimethyl adipimidate cross-linked bovine hemoglobin and glutaraldehyde cross-linked hemoglobin also were incubated at 4° C over a more extended time period. Samples were taken at time intervals, and die emergemoglobin content was determined as described above.
  • the dimediyl adipimidate cross-linked, glutaraldehyde cross- linked, and unmodified hemoglobin samples contained 2.5%, 8.0%, and 3.5% expectmoglobin, respectively, at the start of the incubation.
  • d e percentages of emanatmoglobin were 8.9%, 44.4%, and 8%, respectively, for the dimediyl adipimidate cross- linked, glutaraldehyde cross-linked, and unmodified bovine hemoglobin samples, respectively.
  • dimethyl adipimidate cross-linked and glutaraldehyde cross-linked bovine hemoglobin were measured after incubation for 28 days at 4° C in die same phosphate buffer as described above. After 28 days d e dimethyl adipimidate cross-linked bovine hemoglobin increased from 2.5% to 9.6% methemoglobin. Over the same time period the glutaraldehyde cross-linked hemoglobin increased from 8.0% to 23.5% methemoglobin.
  • Preparative size exclusion chromatography was utilized to remove low molecular weight species, i.e. ⁇ 64,000 daltons, from dimethyl adipimidate cross-linked bovine hemoglobin.
  • Dimethyl adipimidate cross-linked hemoglobin, 40 mg/ml was applied to a 2.5 X 90 cm column of Sephacryl S-200 HR (Pharmacia) equilibrated in 0.025 M sodium phosphate, 0.15 M NaCl, pH 7.4, at 4° C
  • the loading volume was 1% of the column bed volume, and the flow rate was 0.45 ml/min.
  • Peaks from chromatography were pooled, and die pooled samples were analyzed by SEC- HPLC on a Superose 12 column (as described above) to determine d e molecular weight distribution of hemoglobin species within diem.
  • the pre-column or load sample also was analyzed on die Superose 12 column.
  • Preparative size exclusion chromatography separated die DMA cross-linked hemoglobin into two major- fractions.
  • Fraction 1 contained die higher molecular weight cross-linked hemoglobin species, and represented 51.3% of the total recovered hemoglobin.
  • Fraction 2 contained cross-linked hemoglobin of molecular weight less man 64,000.
  • SEC-HPLC of the pre- column cross-linked hemoglobin fraction indicated it to contain 2.6% as > 400,000 daltons, 47.2% > 4,000 daltons, and 50.2% ⁇ 64,000 daltons.
  • purified fraction 1 from preparative size exclusion chromatography contained 4.7% as > 400,000 daltons, 92.7% as > 64,000 daltons, and 2.6% as ⁇ 64,000 daltons. This method was successful at removing d e lower molecular weight hemoglobin species.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Composition d'hémoglobine réticulée par une imidoester utilisée dans le transport d'oxygène vers des cellules vivantes et exemptes de toute impureté, présentant un P 50 de Hg d'au moins 13 mM et dont la forme prédominante est celle d'un tétramère. De préférence, la composition d'hémoglobine réticulée a une masse moléculaire prédominante d'au moins 64000. L'hémoglobine purifiée et réticulée a une stabilité de réticulation améliorée à l'auto-oxydation et elle peut être utilisée pour remplacer le sang chez des mammifères ou comme fluide de transport d'oxygène.
PCT/US1991/007155 1990-11-29 1991-10-03 Compositions d'hemoglobine reticulees par un imidoester WO1992009630A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP91917174A EP0559655B1 (fr) 1990-11-29 1991-10-03 Compositions d'hemoglobine reticulees par un imidoester
PL91299380A PL167340B1 (pl) 1990-11-29 1991-10-03 Sposób wytwarzania usieciowanej hemoglobiny PL
SK54993A SK54993A3 (en) 1990-11-29 1991-10-03 Imidoester cross-linked hemoglobin compositions
JP3516187A JPH06502848A (ja) 1990-11-29 1991-10-03 イミドエステル架橋ヘモグロビン組成物
AU85466/91A AU650287B2 (en) 1990-11-29 1991-10-03 Imidoester cross-linked hemoglobin compositions
CZ93854A CZ281912B6 (cs) 1990-11-29 1991-10-03 Směs hemoglobinu síťovaného imidoesterem a způso b její výroby
DE69108258T DE69108258T2 (de) 1990-11-29 1991-10-03 Mit imidoester quer-vernetzte hämoglobinzusammensetzungen.
US08/065,170 US5362855A (en) 1990-11-29 1993-05-20 Imidoester cross-linked hemoglobin compositions
NO93931956A NO931956L (no) 1990-11-29 1993-05-28 Imidoesterkryssbundne hemoglobinpreparater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61984090A 1990-11-29 1990-11-29
US619,840 1990-11-29

Publications (1)

Publication Number Publication Date
WO1992009630A1 true WO1992009630A1 (fr) 1992-06-11

Family

ID=24483529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/007155 WO1992009630A1 (fr) 1990-11-29 1991-10-03 Compositions d'hemoglobine reticulees par un imidoester

Country Status (22)

Country Link
US (2) US5362855A (fr)
EP (1) EP0559655B1 (fr)
JP (1) JPH06502848A (fr)
AT (1) ATE119917T1 (fr)
AU (1) AU650287B2 (fr)
CA (1) CA2093650A1 (fr)
CZ (1) CZ281912B6 (fr)
DE (1) DE69108258T2 (fr)
DK (1) DK0559655T3 (fr)
ES (1) ES2069908T3 (fr)
FI (1) FI932461A0 (fr)
HU (2) HUT64571A (fr)
IE (1) IE914144A1 (fr)
IL (1) IL99785A (fr)
MX (1) MX9102239A (fr)
NO (1) NO931956L (fr)
NZ (1) NZ240377A (fr)
PL (1) PL167340B1 (fr)
PT (1) PT99666A (fr)
SK (1) SK54993A3 (fr)
WO (1) WO1992009630A1 (fr)
ZA (1) ZA918348B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506123A (ja) * 1993-03-16 1995-07-06 ヘモソール　インコーポレイテッド 酸化開環サッカライドによるヘモグロビンの選択的架橋
EP0685492A2 (fr) * 1994-05-31 1995-12-06 Wolfgang Prof. Dr.Dr. Barnikol Procédé de préparation d'hyperpolymères d'hémoglobine de poids moléculaire uniforme
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981716A (en) * 1995-06-07 1999-11-09 Gruppo Lepettit, S.P.A. Process for the purification of proteins
FR2736930B1 (fr) * 1995-07-17 1997-09-19 Biocem Procede de production, par des cellules vegetales, de proteines heminiques, proteines ainsi obtenues et produits contenant ces proteines
US5872015A (en) * 1996-05-10 1999-02-16 Board Of Trustees Of The University Of Illinois Molecular diversity screening method
CA2270599C (fr) * 1996-11-05 2005-06-14 Challenge Bioproducts Co., Ltd. Modification chimique de materiaux biomedicaux par la genipine
US7282220B1 (en) 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
US7449339B2 (en) * 1999-11-23 2008-11-11 Nir Diagnostics Inc. Spectroscopic method and apparatus for total hemoglobin measurement
US6949384B2 (en) * 2001-12-21 2005-09-27 Spectromedical Inc. Method for monitoring degradation of Hb-based blood substitutes
US7135553B2 (en) * 2003-01-29 2006-11-14 Northfield Laboratories, Inc. Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing
US7135554B1 (en) 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
DE102011105525B4 (de) * 2011-06-24 2015-03-26 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid
AU2018304174A1 (en) 2017-07-18 2020-02-06 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
US20200393472A1 (en) * 2018-04-18 2020-12-17 Sekisui Medical Co., Ltd. Haemoglobin analysis method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
EP0181033A1 (fr) * 1984-11-05 1986-05-14 Akzo N.V. Contrôle pour analyseurs du gaz du sang et détermination d'hémoglobine
EP0195558A2 (fr) * 1985-03-18 1986-09-24 University Of Iowa Research Foundation Composition d hémoglobines réticulées en alpha-alpha
EP0361720A1 (fr) * 1988-09-08 1990-04-04 Technion Research & Development Foundation Ltd. Substitut du sang à base d'hémoglobine et méthode de préparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
ES2032802T5 (es) * 1986-11-10 2004-01-16 Biopure Corporation Sucedaneo de sangre semisintetico extrapuro.
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
EP0181033A1 (fr) * 1984-11-05 1986-05-14 Akzo N.V. Contrôle pour analyseurs du gaz du sang et détermination d'hémoglobine
EP0195558A2 (fr) * 1985-03-18 1986-09-24 University Of Iowa Research Foundation Composition d hémoglobines réticulées en alpha-alpha
EP0361720A1 (fr) * 1988-09-08 1990-04-04 Technion Research & Development Foundation Ltd. Substitut du sang à base d'hémoglobine et méthode de préparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 102, No. 19, 13 May 1985, Columbus, Ohio, US, R.J. FERRIS, "The Crosslinking of Human Met-Hemoglobin with (c14)Dimethyl Adipimidate", Abstract No. 162530, page 252; & CAN. J. BIOCHEM. CELL. BIOL., Vol. 63, No. 3, 1985, pages 195-203. *
CHEMICAL ABSTRACTS, Vol. 91, No. 25, 17 December 1979, Columbus, Ohio, US, R. PENNATHUR DAS, "Modification of Hemoglobin A with Dimethyl Adipimidate", Abstract No. 205961Q, page 211; & BIOCHIM. BIOPHYS. ACTA, Vol. 580, No. 2, 1979, pages 356-365. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506123A (ja) * 1993-03-16 1995-07-06 ヘモソール　インコーポレイテッド 酸化開環サッカライドによるヘモグロビンの選択的架橋
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
EP0685492A2 (fr) * 1994-05-31 1995-12-06 Wolfgang Prof. Dr.Dr. Barnikol Procédé de préparation d'hyperpolymères d'hémoglobine de poids moléculaire uniforme
EP0685492A3 (fr) * 1994-05-31 1996-07-10 Barnikol Wolfgang Procédé de préparation d'hyperpolymères d'hémoglobine de poids moléculaire uniforme.
EP1097943A1 (fr) * 1994-05-31 2001-05-09 SanguiBioTech AG Procédé de préparation d'hyperpolymères d'hémoglobine de poids moléculaire uniforme
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product

Also Published As

Publication number Publication date
HU9301563D0 (en) 1993-09-28
IL99785A (en) 1996-05-14
CZ281912B6 (cs) 1997-03-12
CZ85493A3 (en) 1994-02-16
EP0559655A1 (fr) 1993-09-15
IE914144A1 (en) 1992-06-03
IL99785A0 (en) 1992-08-18
DK0559655T3 (da) 1995-07-24
US5521154A (en) 1996-05-28
FI932461A (fi) 1993-05-28
MX9102239A (es) 1992-07-08
EP0559655B1 (fr) 1995-03-15
SK54993A3 (en) 1993-10-06
CA2093650A1 (fr) 1992-05-30
PT99666A (pt) 1992-10-30
NO931956D0 (no) 1993-05-28
AU8546691A (en) 1992-06-25
HUT64571A (en) 1994-01-28
FI932461A0 (fi) 1993-05-28
NO931956L (no) 1993-05-28
AU650287B2 (en) 1994-06-16
ES2069908T3 (es) 1995-05-16
DE69108258D1 (de) 1995-04-20
ATE119917T1 (de) 1995-04-15
HU211703A9 (en) 1995-12-28
DE69108258T2 (de) 1995-08-10
NZ240377A (en) 1993-01-27
JPH06502848A (ja) 1994-03-31
US5362855A (en) 1994-11-08
ZA918348B (en) 1993-04-19
PL167340B1 (pl) 1995-08-31

Similar Documents

Publication Publication Date Title
US5362855A (en) Imidoester cross-linked hemoglobin compositions
US5264555A (en) Process for hemoglobin extraction and purification
US4598064A (en) Alpha-alpha cross-linked hemoglobins
EP0231236B1 (fr) Purification de l'hemoglobine et hemoglobine modifiee par chromatographie par affinite
CA1273294A (fr) Production d'hemoglobines a liaison croisee a-a en grandes quantites
US4704274A (en) Method for the purification of LPF-HA
JP2000513377A (ja) プリオンのクロマトグラフィー除去方法
JP3438735B2 (ja) 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法
FI104722B (fi) Pyridoksiloidun hemoglobiinin valmistusmenetelmä
GB2221911A (en) Purification of hemoglobin and methemoglobin by bioselective elution
JPH0381290A (ja) 精製されたアルブミン溶液の製造方法
CA2072081C (fr) Polyhemoglobine stabilisee par des derives de la purine et par le glutathion
US5349054A (en) Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin
EP0446582A1 (fr) Méthode de production de l'interféron gamma humain recombinant sans cystéine et sa méthionine à l'extrémité NH2-terminale
US5334705A (en) Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
KR100361894B1 (ko) 치환크로마토그라피방법및정제된헤모글로빈생성물
CN116410295A (zh) 一种大肠杆菌表达物的纯化方法
Pennathur-Das et al. Modification of hemoglobin S with dimethyl adipimidate contribution of inter-tetrameric cross-linking to changes in properties
Hsia et al. Quality control of hemoglobin-based blood substitutes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2093650

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991917174

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1993-854

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 08065170

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 54993

Country of ref document: SK

Ref document number: 932461

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991917174

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1993-854

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1991917174

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1993-854

Country of ref document: CZ

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)